



FOR IMMEDIATE RELEASE
JANUARY 4, 2011

For Further Information:
Susan J. Lewis, 303-804-0494,
slewis@pairelations.com

**CLINICAL RESEARCH ADVANTAGE, INC. INTRODUCES SERVICES IN
COLORADO SPRINGS, COLORADO**

*Clinical Trials Management Company Begins Local Operations;
Facilitates Conducting of a Range of Clinical Trials for New Investigational Treatments*

Colorado Springs, Colo. ...January 4, 2011 ... Clinical Research Advantage, Inc., (CRA), a provider of a range of research services to pharmaceutical companies and clinical research organizations (CROs), announced today its expansion into the Colorado Springs market with the opening of two local area offices.

CRA has forged a partnership with a leading medical practice in the area whose physicians serve as principal investigators of the clinical trials it manages and oversees. As a leading trial management organization (TMO), CRA helps clinical trial sponsors bring drugs to market more quickly and efficiently. CRA offers an innovative mechanism for medical professionals to conduct phase II-IV clinical research trials. With CRA, pharmaceutical and biotech companies as well as various study sponsors have a resource for conducting clinical trials seamlessly, efficiently and effectively. CRA is comprised of dozens of community-based investigators based throughout the country, and its sites are headed by an experienced staff of clinical research coordinators.

Local CRA offices in Colorado Springs include one at Colorado Springs Health Partners in Briargate – 2405 Research Parkway in Briargate (office of Kari Uusinarkaus, M.D.; Dennis Schneider, M.D. and Gordon Golden, M.D.); and on the east side at 6340 Barnes Road (office of John Speer, M.D., Max Nevarez, M.D., Royce Solano, M.D. and Alan Garscadden, M.D.).

Current plans call for several more sites to open in the Colorado Springs area by summer 2011.

The new offices and principal investigators focus on trials and maintenance studies relating to the various diagnoses as well as others within the realm of family and internal medicine. At Briargate, studies underway include irritable bowel syndrome-diarrhea, hypercholesterolemia, Type II Diabetes Naïve (not currently being treated with anti-diabetic medication) and acute coronary syndrome with or without Type II Diabetes. Upcoming studies include Type II Diabetes and hypertriglyceridemia. At the east office, studies being conducted include those for chronic obstructive pulmonary disease, irritable bowel syndrome-diarrhea, pediatric influenza vaccine, and Type II Diabetes with cardiovascular risk. Upcoming studies at this office include opioid-induced constipation and Type II diabetes.

- more -

Concurrent with the office openings, CRA named Monica Garcia, BS, CCRC, to the post of region manager. Garcia heads the Colorado Springs-area operations and has worked with CRA for the past six years. She is certified through the Association of Clinical Research Professionals, an industry trade organization that serves as a resource for clinical research professionals engaged in the pharmaceutical, biotechnology and medical device industries, and those in hospital, academic medical centers and physician office settings.

Since CRA was acquired in 2007 by Mark Hanley, who serves as chief executive officer, and David Bruggeman, president and chief operating officer, the company has grown from six to 23 sites, doubled the number of employees and substantially increased the revenue base.

“The key to CRA’s success lies in the partnerships we forge and maintain with research departments within established medical practices. Our model positions CRA’s own research staff and coordinators right in the heart of the physician’s office, which helps cultivates the enrollment of reliable, qualified subjects into clinical trials and ensures better compliance, due to the patient’s close proximity to the physicians,” Hanley noted.

“Additionally, healthcare reform is calling for effectiveness and comparative studies to be performed on behalf of a range of medications. This opens the doors for additional clinical trials to be conducted to help ensure quality care, safety and cost containment across the board,” Hanley explained.

Bruggeman added: “Colorado Springs is a growing market for CRA. We have expanded rapidly here, with 17 studies already underway and many patients participating. This expansion presented us with an opportunity to partner with nearly 100 physicians, which compromise the largest group in the area. We are excited about the relationship and the trials we are bringing the community.”

Tempe, Ariz.-based Clinical Research Advantage, Inc. (CRA) is a provider of a range of research services to pharmaceutical companies and clinical research organizations (CROs). As a leading trial management organization (TMO), CRA operates from 23 sites across 12 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Since its inception two decades ago, CRA has successfully completed more than 1,600 clinical trial studies on behalf of its clients. For more information, please visit www.crastudies.com.

###